AOD 9604 vs CJC-1295: How These Two Peptides Compare

AOD 9604 and CJC-1295 are two research peptides that work through completely different pathways. AOD 9604 is a modified fragment of human growth hormone studied for fat metabolism, while CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that raises growth hormone and IGF-1. Neither peptide is FDA-approved for human use in the United States, and no head-to-head human trial has ever compared the two directly.

That distinction matters, because the two are often discussed as if they were interchangeable fat-loss tools. They are not. Below is a plain-English breakdown of how each one works, what the research actually shows, and where the comparison falls apart.

What AOD 9604 Is and How It Works

AOD 9604 is a 16-amino-acid fragment of human growth hormone, covering residues 177–191 with an added tyrosine at one end. It was engineered to isolate the region of hGH linked to fat metabolism while avoiding the parts that influence blood sugar and IGF-1.

Because it does not drive IGF-1 the way full growth hormone does, AOD 9604 is usually described as a fat-loss peptide rather than a growth peptide. Key points from the published research:

• Mechanism: studied for effects on lipolysis (fat breakdown) and fat oxidation.
• IGF-1: does not appear to raise IGF-1 meaningfully in the studies published so far.
• Human results: early trials showed modest, inconsistent changes in fat mass, and the compound failed to win approval as an obesity drug.
• Typical research dose: most published and online protocols cite 250–500 mcg per day by subcutaneous injection.

AOD 9604 is not FDA-approved for human use in the United States. The FDA has also stated that AOD-9604 is not a lawful dietary ingredient, which is why it cannot legally appear in over-the-counter fat-loss supplements.

What CJC-1295 Is and How It Works

CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It is a shortened, modified version of GHRH(1-29) built to resist rapid breakdown by enzymes in the blood, so it keeps signaling the pituitary gland to release growth hormone.

Unlike AOD 9604, CJC-1295 raises both growth hormone and IGF-1, which is the main reason people research it for body composition, recovery, and sleep quality. CJC-1295 is not FDA-approved for human use, and its original developer never brought it to market.

CJC-1295 With DAC vs. Without DAC

There are two versions of this peptide, and confusing them is one of the most common mistakes in peptide research.

CJC-1295 with DAC binds to albumin in the bloodstream, which is what stretches its half-life out to about a week. The version without DAC clears so quickly that it is almost always paired with a growth hormone-releasing peptide such as ipamorelin.

AOD 9604 vs CJC-1295: Side-by-Side Comparison

In short, AOD 9604 targets fat tissue directly, while CJC-1295 works upstream by turning up growth hormone output. There is no head-to-head human trial comparing AOD 9604 with CJC-1295, so any claim that one clearly beats the other is an extrapolation rather than evidence.

Can You Stack AOD 9604 and CJC-1295?

Some research protocols do combine the two, on the theory that one handles fat metabolism while the other raises growth hormone and IGF-1. That is what most people mean by an aod 9604 and cjc-1295 stack.

The honest caveats are worth spelling out:

• No human trial has tested the combination, so dosing and safety data simply do not exist.
• CJC-1295 already raises IGF-1, and stacking adds a second injectable with its own risk profile.
• Both compounds are injectables of uncertain purity when purchased from gray-market vendors.

A related question that comes up constantly is aod 9604 vs cjc-1295 ipamorelin. Adding ipamorelin changes the comparison entirely, because ipamorelin amplifies natural growth hormone pulses rather than acting on fat tissue at all.

How AOD 9604 Compares to Other Fat-Loss Compounds

AOD 9604 is not the only compound in this conversation, and the alternatives work in meaningfully different ways.

The comparison aod 9604 vs tesamorelin is a useful example, because tesamorelin is an FDA-approved GHRH analog that raises IGF-1 while AOD 9604 is unapproved and does not raise IGF-1.

The comparison aod 9604 vs mots-c is an even sharper contrast, since MOTS-c is a mitochondrial-derived peptide studied for metabolic and insulin-related effects rather than a growth hormone fragment.

The comparison aod 9604 vs retatrutide puts an unapproved research peptide next to an investigational triple GLP-1/GIP/glucagon agonist that has produced large phase 3 weight-loss results and is still awaiting regulatory review.

The pattern holds: compounds with substantial human data and regulatory review sit in a different category from research chemicals like AOD 9604 and CJC-1295.

Safety, Legality, and Buying Considerations

AOD 9604 appeared reasonably well tolerated in the limited trials published, with injection-site reactions being the most common complaint. CJC-1295 carries the class effects of raising growth hormone and IGF-1, which can include fluid retention, joint discomfort, and changes in how the body handles blood sugar.

Safety and legal facts worth repeating:

• Neither AOD 9604 nor CJC-1295 is FDA-approved for human use.
• AOD-9604 is not a lawful dietary ingredient in the United States.
• Both peptides are banned in sport by the World Anti-Doping Agency.
• Research-grade peptides sold online are frequently mislabeled or under-purified.

Anyone considering either compound should talk with a licensed healthcare professional first, especially if they take medication for diabetes or a thyroid condition. This article is informational only and is not medical advice.